

MDS-LANCET LABORATORIES (GH) LTD. East Legon Laboratory (Head Ofice)

www.mds-lancet.com

Key to Diagnostic Excellence

in partnership with Lancet Laboratories South Africa

Patient:

MARGARETTE ABUGA

ISO/IEC 15189 :2012 ACCREDITED LABORATORY

Doctors Ref NOT AVAILABLE

Page: 2 Lab Ref : 706198573 / 14/01/18 1031

BIOCHEMISTRY

Reference Result Test triglyceride levels greater than 5.7 mmol/L should be treated first to prevent pancreatitis. The target for non-HDL cholesterol in persons with elevated fasting triglycerides is 0.8 mmol/L HIGHER than their LDL cholesterol target. < 4.1 3.5 > S-CHOL./HDL RATIO < 1.70 2.15 mmol/L > S-TRIGLYCERIDE > COMMENT TREATMENT TARGETS FOR EACH RISK GROUP AS DEFINED BY FRAMINGHAM RISK SCORING SYSTEM(FRS) : : TOTAL : LDL-C : Non HDL-C : ApoB :RISK (FRS) : CHOLESTEROL : mmol/L : mmol/L : g/L : : ** Very : : : High : < 4.0 : < 1.8 : < 2.6 : < 0.8 : < 3.3 : < 1.0 : High : < 4.5 : < 2.5 : Moderate/: < 5.0 : < 3.0 : < 3.8 : :.Low....:...:....:

- ** Very high risk subjects are:
- 1) Established atherosclerotic disease,
- 2) Type 2 DM
- 3) Type 1 DM with micro-albuminuria and proteinuria
- 4) Genetic Dyslipidaemia
- 5) Chronic Kidney Disease

Reference: South African Dyslipidaemia Guidelines 2012.

For consultation by referring doctors only, please call:

Dr Stan Zail +2711 358 0750

Dr David Rambau +2712 483 0237

ODOI, F:GH_EL_ENQ_PRT:REPRINT.a4:4085017

** End of Report **